Published by Frank Prenesti on 7th August 2026
(Sharecast News) - Shares in Oxford Biomedica tanked by a quarter on Friday after the cell and gene therapy manufacturer slashed its full year revenue and margins forecast citing short‑term client ordering delays, programme deferrals and operational delays at its North Carolina facility.